drug · small molecule
lenvatinib mesylate
Marketedupdated 3mo agoby Eisai Co Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.
indications
investigational
Colorectal CancerMelanoma
targets
Vascular endothelial growth factor receptor
all catalysts(2)
Trials studying lenvatinib mesylate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 19, 2026
30 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (40)
- Nov 15, 2038patentUS 12226409*PED
- Nov 15, 2038patentUS 12226409*PED
- May 15, 2038method-of-use (U-4146)US 12226409
- May 15, 2038method-of-use (U-4146)US 12226409
- Sep 3, 2036patentUS 12083112*PED
- Sep 3, 2036patentUS 12083112*PED
- Aug 23, 2036patentUS 11090386*PED
- Aug 23, 2036patentUS 11090386*PED
- Mar 3, 2036method-of-use (U-3997)US 12083112
- Mar 3, 2036method-of-use (U-3997)US 12083112
- Feb 26, 2036patentUS 10259791*PED
- Feb 26, 2036patentUS 10259791*PED
- Feb 26, 2036patentUS 10407393*PED
- Feb 26, 2036patentUS 10407393*PED
- Feb 26, 2036patentUS 11186547*PED
- Feb 26, 2036patentUS 11186547*PED
- Feb 23, 2036method-of-use (U-3519)US 11090386
- Feb 23, 2036method-of-use (U-3519)US 11090386
- Aug 26, 2035compositionUS 10259791
- Aug 26, 2035compositionUS 10259791
- Aug 26, 2035compositionUS 10407393
- Aug 26, 2035compositionUS 10407393
- Aug 26, 2035compositionUS 11186547
- Aug 26, 2035compositionUS 11186547
- Apr 4, 2031patentUS 12508313*PED4.6y
- Apr 4, 2031patentUS 12508313*PED4.6y
- Oct 4, 2030formulationUS 125083134.1y
- Oct 4, 2030formulationUS 125083134.1y
- Jan 27, 2028patentUS 9006256*PED1.4y
- Jan 27, 2028patentUS 9006256*PED1.4y
- Jul 27, 2027method-of-use (U-1695)US 9006256341d
- Jul 27, 2027method-of-use (U-1695)US 9006256341d
- Mar 19, 2027patentUS 7612208*PED211d
- Mar 19, 2027patentUS 7612208*PED211d
- Sep 19, 2026compositionUS 761220830d
- Sep 19, 2026compositionUS 761220830d
- Apr 24, 2026patentUS 7253286*PED
- Apr 24, 2026patentUS 7253286*PED
- Oct 24, 2025compositionUS 7253286
- Oct 24, 2025compositionUS 7253286
FDA exclusivities (8)
- Oct 3, 2027PEDPediatric (6mo bonus)1.1y
- Oct 3, 2027PEDPediatric (6mo bonus)1.1y
- Apr 3, 2027M-14Method (3y)226d
- Apr 3, 2027M-14Method (3y)226d
- Feb 15, 2026PEDPediatric (6mo bonus)
- Feb 15, 2026PEDPediatric (6mo bonus)
- Aug 15, 2025ODE-196Orphan Drug (7y)
- Aug 15, 2025ODE-196Orphan Drug (7y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that